Benefits
Upper respiratory tract infection support
Multiple randomized controlled trials of yeast beta-1,3/1,6 glucan have shown reductions in the number, severity, and/or duration of upper respiratory tract infection symptoms in adults and children, with the strongest signals in physiologically stressed populations (marathon runners, daycare-aged children, individuals with recurring infections).
Innate immune cell activation
Beta-1,3/1,6 glucans engage pattern-recognition receptors on innate immune cells, supporting baseline activity of neutrophils, macrophages, and natural killer cells. The result is a 'trained' or 'primed' innate immune response that may respond more effectively to common pathogen challenges.
Adjunct during periods of physiologic stress
Periods of heavy exercise, demanding work travel, or seasonal viral exposure are commonly cited use-cases for beta-1,3/1,6 glucan supplementation, based on the trial evidence pattern showing larger effects in stressed populations than in well-rested healthy controls.
Mood and well-being support during illness
In the Wellmune® marathon athlete trial, beta-glucan supplementation was associated with improvements in mood-state measures (reduced fatigue, tension, anger, and confusion; increased vigor) alongside reduced URTI symptoms, suggesting a broader well-being benefit during stress-recovery.
Mechanism of action
Dectin-1 receptor engagement on innate immune cells
Beta-1,3 glucans bind Dectin-1, a C-type lectin pattern-recognition receptor on macrophages, neutrophils, and dendritic cells. Receptor engagement activates Syk and downstream signaling, modulating cytokine production and phagocytic activity in a controlled manner.
Complement receptor 3 (CD11b/CD18) binding
Soluble beta-glucans bind the lectin site of complement receptor 3 on neutrophils and natural killer cells, priming these cells for enhanced cytotoxic and phagocytic activity against complement-opsonized targets — one of the classical mechanisms characterized for beta-glucan immunomodulation.
Trained immunity in innate cells
Repeated beta-glucan exposure has been shown to induce epigenetic and metabolic reprogramming in monocytes and macrophages — a phenomenon termed 'trained immunity' — leaving these cells more responsive to subsequent pathogen challenge over weeks to months.
Gut-associated lymphoid tissue interaction
Orally administered beta-glucans are taken up by M cells of the Peyer's patches and processed by gut-associated immune cells, which then traffic to other immune compartments. This mechanism explains how oral particulate yeast beta-glucans can produce systemic immune effects.
Clinical trials
Randomized, double-blind, placebo-controlled, multicentric trial of insoluble yeast (1,3)-(1,6)-beta-glucan (900 mg/day) vs placebo in 162 healthy adults with recurring infections for 16 weeks. Outcomes: number of symptomatic common cold infections, symptom score, sleep disturbance. Published in European Journal of Nutrition.
162 healthy adults with recurring infections; 16-week intervention.
Yeast (1,3)-(1,6)-beta-glucan supplementation reduced the number of symptomatic common cold infections by 25% vs placebo (p=0.041), reduced mean symptom score by 15%, and significantly reduced sleep disturbance from cold episodes. Supports the immune-supportive positioning of yeast beta-glucans in adults with recurring infections.
Randomized, double-blind, placebo-controlled trial of Wellmune WGP® beta-1,3/1,6 glucan at 250 mg/day or 500 mg/day vs placebo in 75 marathon runners for 4 weeks following the Carlsbad Marathon. Outcomes: upper respiratory tract infection symptoms, mood state. Published in Journal of Sports Science and Medicine.
75 marathon athletes; 4-week post-race intervention.
Beta-glucan groups reported significantly fewer URTI symptoms and improvements in mood-state measures (reduced confusion, fatigue, tension, anger; increased vigor) vs placebo. Supports yeast beta-glucan use in the post-exercise immune-stress recovery window.
Review summarizing the immunomodulatory mechanisms of beta-glucans across decades of preclinical and clinical research, including pattern-recognition receptor binding, innate immune cell priming, and trained immunity. Published in Journal of Immunotoxicology.
Mechanism review across in vitro, animal, and human studies.
Beta-glucans act as biological response modifiers through innate immune receptor engagement (Dectin-1, CR3) and trained-immunity programs. The review notes that despite nearly 150 years of research, exact mechanisms are still being clarified, but the immunomodulatory effects are reproducible across preparations and species.